Our data shows that IDH1/2mt gliomas are distinct when compared to other IDH1/2mt tumours in that they have a disproportionally high percentage of IDH1R132H mutations and raise the attractive clinical association between different rarer (codon 132) mutations and outcome. Here, IDH1 is linked to central nervous system cancer.